1. Home
  2. SNGX vs NCEL Comparison

SNGX vs NCEL Comparison

Compare SNGX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.15

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.50

Market Cap

10.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
NCEL
Founded
1987
2008
Country
United States
Switzerland
Employees
N/A
11
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.3M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
SNGX
NCEL
Price
$1.15
$2.50
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
174.9K
17.1K
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
N/A
EPS
N/A
N/A
Revenue
$119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.83
52 Week High
$6.23
$4.70

Technical Indicators

Market Signals
Indicator
SNGX
NCEL
Relative Strength Index (RSI) 48.10 53.76
Support Level $1.11 $2.50
Resistance Level $1.22 $3.16
Average True Range (ATR) 0.05 0.19
MACD 0.00 0.05
Stochastic Oscillator 57.58 84.15

Price Performance

Historical Comparison
SNGX
NCEL

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

Share on Social Networks: